Lianhua Qingke tablets,a patented traditional Chinese medicine that has validated clinical efficacy for treating cough caused by severe acute respiratory syndrome coronavirus 2 infection,lack rigorous evidence-based r...Lianhua Qingke tablets,a patented traditional Chinese medicine that has validated clinical efficacy for treating cough caused by severe acute respiratory syndrome coronavirus 2 infection,lack rigorous evidence-based research evaluating their effect on long coronavirus disease(COVID)cough.A randomized,double-blind,placebo-controlled,multicenter clinical study was conducted among patients with long COVID cough from 19 hospitals and 23 community health centers in China.Patients were randomized 1:1 to receive either Lianhua Qingke tablets or placebo orally for 14 days(four tablets,1.84 g,three times a day).The primary endpoint indicator was the disappearance of cough,with the remission of cough also considered.Among 482 randomized patients,480(full analysis set 480;per-protocol set 470;safety set 480)were included in the primary analysis.According to the full analysis,the time until cough disappearance was significantly shorter in the trial group than in the control group,with a significant increase in the 14-day cough disappearance rate.Accordingly,the time to cough remission was significantly shorter in the trial group than in the control group.The change in the total symptom score was significantly greater in the trial group than in the control group on days 7 and 14,consistent with the results indicated by the visual analog scale(VAS)and cough evaluation test(CET)scores.No serious adverse events were recorded during the study.Lianhua Qingke tablets significantly improved the clinical symptoms of patients with long COVID cough.展开更多
目的评价中西医结合治疗急性痛风性关节炎(AGA)的临床疗效。方法计算机检索中国知网、维普、万方、中国生物医学文献数据库及PubMed,Embase,Cochrane,Web of Science数据库,检索时限为自建库起至2021年8月。采用Cochrane偏倚风险工具评...目的评价中西医结合治疗急性痛风性关节炎(AGA)的临床疗效。方法计算机检索中国知网、维普、万方、中国生物医学文献数据库及PubMed,Embase,Cochrane,Web of Science数据库,检索时限为自建库起至2021年8月。采用Cochrane偏倚风险工具评价纳入文献质量,采用RevMan 5.3统计学软件进行Meta分析,采用漏斗图和Begg's检验分析发表偏倚。结果共纳入12篇文献。Meta分析结果显示,与单纯西医治疗比较,中西医结合治疗可显著提高AGA患者临床总有效率[OR=3.51,95%CI(2.32,5.31),P<0.05],显著降低血尿酸水平[MD=-38.25,95%CI(-57.33,-19.16),P<0.05],视觉模拟量表(VAS)评分[MD=-0.93,95%CI(-1.08,-0.78),P<0.05],红细胞沉降率[MD=-5.16,95%CI(-7.07,-3.24),P<0.05];C反应蛋白水平[SMD=-0.89,95%CI(-1.22,-0.56),P<0.05]。两种治疗方法的药品不良反应发生率[RR=0.50,95%CI(0.24,1.04),P>0.05]无显著差异。结论中西医结合治疗与单纯西医治疗相比,能显著提高AGA患者临床总有效率,同时降低VAS评分、红细胞沉降率及血尿酸、C反应蛋白水平。展开更多
目的:探讨中西医结合在糖尿病性冠心病中的临床疗效。方法:筛选2012年1月—2015年1月我院收治的糖尿病性冠心病患者98例,作为研究对象。采用随机数表法将其分为观察组与对照组,每组患者49例,其中对照组患者单纯接受常规西药治疗,观察组...目的:探讨中西医结合在糖尿病性冠心病中的临床疗效。方法:筛选2012年1月—2015年1月我院收治的糖尿病性冠心病患者98例,作为研究对象。采用随机数表法将其分为观察组与对照组,每组患者49例,其中对照组患者单纯接受常规西药治疗,观察组在对照组基础上加服益气滋阴活血方,两组患者持续性治疗4周后根据患者血脂、血糖及心电图检查结果评价治疗总有效率。结果:两组患者干预前比较FPG、2 h PG比较无显著差异(P>0.05),干预6个月后比较观察组患者FPG及2 h PG水平明显低于对照组,P<0.05,具有统计学意义;观察组患者治疗后显效23例,有效20例,总有效率达87.8%,与对照组患者治疗后总有效率比较存在显著差异,P<0.05,具有统计学意义。结论:在西药治疗的基础上加服益气滋阴活血方可显著提高糖尿病性冠心病的临床治疗效果,改善患者生活质量,安全性较高,具有临床应用及推广价值。展开更多
基金supported by National Multidisciplinary Innovation Team Project of Traditional Chinese Medicine(ZYYCXTD-D-202201)Beijing Key Specialized Department for Major Epidemic Prevention and Control(Construction ProjectJingweiyi[2019]161).
文摘Lianhua Qingke tablets,a patented traditional Chinese medicine that has validated clinical efficacy for treating cough caused by severe acute respiratory syndrome coronavirus 2 infection,lack rigorous evidence-based research evaluating their effect on long coronavirus disease(COVID)cough.A randomized,double-blind,placebo-controlled,multicenter clinical study was conducted among patients with long COVID cough from 19 hospitals and 23 community health centers in China.Patients were randomized 1:1 to receive either Lianhua Qingke tablets or placebo orally for 14 days(four tablets,1.84 g,three times a day).The primary endpoint indicator was the disappearance of cough,with the remission of cough also considered.Among 482 randomized patients,480(full analysis set 480;per-protocol set 470;safety set 480)were included in the primary analysis.According to the full analysis,the time until cough disappearance was significantly shorter in the trial group than in the control group,with a significant increase in the 14-day cough disappearance rate.Accordingly,the time to cough remission was significantly shorter in the trial group than in the control group.The change in the total symptom score was significantly greater in the trial group than in the control group on days 7 and 14,consistent with the results indicated by the visual analog scale(VAS)and cough evaluation test(CET)scores.No serious adverse events were recorded during the study.Lianhua Qingke tablets significantly improved the clinical symptoms of patients with long COVID cough.
文摘目的评价中西医结合治疗急性痛风性关节炎(AGA)的临床疗效。方法计算机检索中国知网、维普、万方、中国生物医学文献数据库及PubMed,Embase,Cochrane,Web of Science数据库,检索时限为自建库起至2021年8月。采用Cochrane偏倚风险工具评价纳入文献质量,采用RevMan 5.3统计学软件进行Meta分析,采用漏斗图和Begg's检验分析发表偏倚。结果共纳入12篇文献。Meta分析结果显示,与单纯西医治疗比较,中西医结合治疗可显著提高AGA患者临床总有效率[OR=3.51,95%CI(2.32,5.31),P<0.05],显著降低血尿酸水平[MD=-38.25,95%CI(-57.33,-19.16),P<0.05],视觉模拟量表(VAS)评分[MD=-0.93,95%CI(-1.08,-0.78),P<0.05],红细胞沉降率[MD=-5.16,95%CI(-7.07,-3.24),P<0.05];C反应蛋白水平[SMD=-0.89,95%CI(-1.22,-0.56),P<0.05]。两种治疗方法的药品不良反应发生率[RR=0.50,95%CI(0.24,1.04),P>0.05]无显著差异。结论中西医结合治疗与单纯西医治疗相比,能显著提高AGA患者临床总有效率,同时降低VAS评分、红细胞沉降率及血尿酸、C反应蛋白水平。
文摘目的:探讨中西医结合在糖尿病性冠心病中的临床疗效。方法:筛选2012年1月—2015年1月我院收治的糖尿病性冠心病患者98例,作为研究对象。采用随机数表法将其分为观察组与对照组,每组患者49例,其中对照组患者单纯接受常规西药治疗,观察组在对照组基础上加服益气滋阴活血方,两组患者持续性治疗4周后根据患者血脂、血糖及心电图检查结果评价治疗总有效率。结果:两组患者干预前比较FPG、2 h PG比较无显著差异(P>0.05),干预6个月后比较观察组患者FPG及2 h PG水平明显低于对照组,P<0.05,具有统计学意义;观察组患者治疗后显效23例,有效20例,总有效率达87.8%,与对照组患者治疗后总有效率比较存在显著差异,P<0.05,具有统计学意义。结论:在西药治疗的基础上加服益气滋阴活血方可显著提高糖尿病性冠心病的临床治疗效果,改善患者生活质量,安全性较高,具有临床应用及推广价值。
